NasdaqGS:KRYSBiotechs
Krystal Biotech (KRYS): Assessing Valuation Following Strong Q3 Results and Global Expansion Moves
Krystal Biotech (KRYS) is drawing fresh attention after reporting strong third quarter results. The report included higher gross margins and impressive revenue from its VYJUVEK therapy. The company is also expanding into Europe, Asia, and the Middle East.
See our latest analysis for Krystal Biotech.
Momentum has clearly been building for Krystal Biotech. After a quieter start to the year, shares have surged more than 40% over the last 90 days, and the one-year total shareholder return now...